WHEATON® Announces Acquisition of CELLine™
News Jul 10, 2012
WHEATON has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corporation.
WHEATON has also entered into a long term strategic partnership with Wilson Wolf Manufacturing Corporation for further product development in high density cell culture devices for the production of concentrated, cell secreted products.
CELLine Flasks are known by their loyal users to be easy to implement and are trusted worldwide for small scale suspension and adherent cultures.
The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small scale bio-production for antibody and protein generation.
Conventional in vivo or in vitro cell culture methods can be laborious, result in low cell density, and require significant purification.
The CELLine Flasks address these three areas of limitation in a single use, repeatable technology.
CELLine Flasks are ready-to-use and disposable, produce high cell density and high product concentration, while significantly reducing culture and processing time.
“We are excited to bring this innovative, high growth technology to WHEATON and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing WHEATON portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, President of WHEATON.
“We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Mechanism Behind Inflammatory Response to Cytoplasmic DNA IdentifiedNews
A team led by LMU‘s Veit Hornung has elucidated the mechanism by which human cells induce inflammation upon detection of cytoplasmic DNA. Notably, the signal network involved differs from that used in the same context in mice.READ MORE
Pathway in Neurons may Contribute to Neurodegenerative DiseaseNews
Pathway has received attention as potential drug target.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE